Ascendis Pharma A/S (ASND) NASDAQ

159.97

-0.0826(-0.05%)

Updated at May 23 11:33AM

Currency In USD

Ascendis Pharma A/S

Address

Tuborg Boulevard 12

Hellerup, 2900

Denmark

Phone

45 70 22 22 44

Sector

Healthcare

Industry

Biotechnology

Employees

1017

First IPO Date

January 28, 2015

Key Executives

NameTitlePayYear Born
Mr. Jan Moller MikkelsenPresident, Chief Executive Officer, Member of Executive Board & Executive Director01960
Mr. Flemming Steen JensenExecutive Vice President of Product Supply & Quality01961
Mr. Scott T. SmithChief Financial Officer, Executive Vice President & Member of Executive Board01974
Ms. Pedersen Anni Lotte Kirstine SonderbjergExecutive Vice President, Chief Administrative Officer & Member of the Executive Board01961
Mr. Michael Wolff Jensen L.L.M.Executive Vice President, Chief Legal Officer & Member of the Executive Board01971
Dr. Kennett Sprogoe Ph.D.Executive Vice President and Head of Research & Product Development01979
Dr. Stina Singel M.D., Ph.D.Executive Vice President & Head of Clinical Development for Oncology01974
Ms. Sherrie GlassChief Business Officer0N/A
Mr. Mads BodenhoffSenior Vice President, Head of Finance & Principal Accounting Officer01969
Mr. Joseph KellyHead of U.S. Commercial of Endocrinology01969

Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.